Compounded Tirzepatide vs Mounjaro
Which Is Right for You? Complete Comparison (2026)
Compounded tirzepatide can cost 70–90% less than Mounjaro. Compare safety, quality, legality, and cost — and what changed in 2025–2026.
Compounded Tirzepatide vs Mounjaro: At a Glance
- ✓Dual GIP + GLP-1 receptor agonist — first in class
- ✓GIP agonism enhances insulin sensitivity in adipose tissue
- ✓~21% mean weight loss at 72 weeks (SURMOUNT-1, 15 mg)
- ✓GIP may moderate GI side effects vs GLP-1-only drugs
- ✓Half-life ~5 days — once-weekly injection
- ✓Dual GIP + GLP-1 receptor agonist — first in class
- ✓GIP agonism enhances insulin sensitivity in adipose tissue
- ✓~21% mean weight loss at 72 weeks (SURMOUNT-1, 15 mg)
- ✓GIP may moderate GI side effects vs GLP-1-only drugs
- ✓Half-life ~5 days — once-weekly injection
Detailed Comparison
| Feature | Compounded Tirzepatide | Mounjaro |
|---|---|---|
| Mechanism | Dual GIP/GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonistBest |
| Dosing | 2.5-15 mg SC weekly | 2.5-15 mg SC weekly |
| Administration | Subcutaneous injection weekly | Subcutaneous injection weekly |
| Half-life | ~5 days | ~5 days |
| FDA Status | FDA-approved: Mounjaro (T2D), Zepbound (obesity) | FDA-approved: Mounjaro (T2D), Zepbound (obesity) |
| Key Trial | Jastreboff AM et al. NEJM 2022 (SURMOUNT-1) — 20.9% weight loss | Jastreboff AM et al. NEJM 2022 (SURMOUNT-1) — 20.9% weight loss |
| Side Effects | Nausea (31%), vomiting, diarrhea, constipation | Nausea (31%), vomiting, diarrhea, constipation |
Which Should You Choose?
Tirzepatide (dual gip/glp-1 receptor agonist) and Tirzepatide (dual gip/glp-1 receptor agonist) serve different clinical roles despite both being in the Dual GIP/GLP-1 agonist space. Tirzepatide first-in-class dual gip and glp-1 receptor agonist that activates two incretin pathways for enhanced weight loss and glycemic control vs single agonists. Tirzepatide first-in-class dual gip and glp-1 receptor agonist that activates two incretin pathways for enhanced weight loss and glycemic control vs single agonists.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Compounded Tirzepatide vs Mounjaro: Frequently Asked Questions
Tirzepatide is a dual gip/glp-1 receptor agonist while Tirzepatide is a dual gip/glp-1 receptor agonist. They differ in mechanism, dosing, and clinical evidence. Your choice should depend on your specific goals and medical history.
Switching should be done under medical supervision. Your prescriber can advise on transition protocols. Track both in Shotlee for comparison data.
Tirzepatide works as a dual gip/glp-1 receptor agonist (2.5-15 mg SC weekly), while Tirzepatide is a dual gip/glp-1 receptor agonist (2.5-15 mg SC weekly). They have different half-lives (~5 days vs ~5 days), side effect profiles, and levels of clinical evidence.
Yes. Shotlee supports tracking any medication or peptide. You can compare your results across different protocols.
Track Compounded Tirzepatide or Mounjaro in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.
📚References & sources
Latest on Compounded Tirzepatide
Eli Lilly Warns of Counterfeit Mounjaro, Zepbound Risks from Impurities
Eli Lilly, maker of Mounjaro and Zepbound, has discovered critical impurities in counterfeit tirzepatide versions mixed with vitamin B12. These compounded drugs pose unknown risks due to chemical reactions and lack of FDA oversight. With one in eight Americans using GLP-1s, experts urge sticking to approved medications.
5 min read
Healthier Happy Selects CoreAge Rx as Top Tirzepatide Online Destination
Independent health platform Healthier Happy has chosen CoreAge Rx as its preferred destination for tirzepatide online, highlighting its physician-supervised telehealth model, straightforward pricing, and direct-to-home delivery. This recognition underscores CoreAge Rx's role in simplifying access to GLP-1 therapies like tirzepatide and semaglutide for metabolic health.
5 min read